HMOX1 and obesity due to melanocortin 4 receptor deficiency: Recently, innovative therapeutic strategies targeting HO-1 and biliverdin have garnered increasing interest for their potential to improve obesity, adipocyte dysfunction, and related metabolic syndrome.